In MASLD patients, both plasma and hepatic BAs concentrations are increased [73,74], while both FXR and TGR5 pathways are downregulated, as demonstrated in animal and human studies [65,70,75,76]. The gene discussed is GPBAR1; the disease is metabolic dysfunction-associated steatotic liver disease.